ReShape Medical racks up $38 mln

San Clemente, California-based ReShape Medical, a weight loss-focused medical device company, has closed $38 million in Series D funding. HealthCor Partners Management LP led the round with participation from Endeavour Vision SA, SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners and Venture Investors.

Genetic medicine company WAVE Life Sciences nets $66 mln

Boston-based genetic medicine company WAVE Life Sciences has closed $66 million in Series B funding. Foresite Capital led the round with participation from other investors that included Fidelity Management and Research Company, New Leaf Venture Partners, Redmile Group, Jennison Associates (on behalf of certain clients), Cormorant Asset Management and RA Capital Management. Leerink Partners served as the placement agent.

101 Views

Advanced Cell Diagnostics rakes in $22 mln

Advanced Cell Diagnostics Inc, a developer of cell and tissue-based diagnostic tests for precision medicine, has secured $22 million in Series C funding. Summit Partners led the round with participation from Kenson Ventures, Morningside Ventures and New Leaf Venture Partners. In addition to the funding, Harrison Miller, a managing director at Summit Partners, has been added to ACD’s board of directors.

New Leaf Venture Partners leads Series B round for Unum Therapeutics

Cambridge, Massachusetts-based Unum Therapeutics, a developer of antibody-directed cellular immunotherapy, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Brace Pharma Capital, Cowen Private Investments, Novo A/S, Sabby Management LLC, Wellington Management Company LLP, Fidelity Biosciences, Atlas Venture and Sanofi-Genzyme BioVentures. In addition to the funding, Dr. Liam Ratcliffe, managing director at New Leaf Venture Partners, has been added to Unum’s board of directors.

181 Views

Dimension Therapeutics nets $65 mln Series B

Cambridge, Massachusetts-based Dimension Therapeutics Inc, which is focused on developing treatments for liver disorders, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Jennison Associates (on behalf of investors), Partner Fund Management, RA Capital Management, Rock Springs Capital, Tourbillon Global Ventures, Fidelity Biosciences and OrbiMed. In addition to the funding, Dr. Mike Dybbs, a partner at New Leaf Venture Partners, has been added to Dimension’s board of directors.

Edge Therapeutics racks up about $72.5 mln

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics’ board of directors.

119 Views

CardioKinetix racks up $50 mln

CardioKinetix, a Menlo Park, Calif.-based medical device firm, has received $50 million in funding. Edwards Lifesciences Corp. led the round with participation from return backers U.S. Venture Partners, Tekla Healthcare Investors, Tekla Life Sciences Investors, SV Life Sciences, Panorama Capital, New Leaf Venture Partners and Lexington Private Equity. CardioKinetix has also inked an agreement with Edwards Lifesciences Corp. that gives the latter company the option to acquire CardioKinetix “based on future regulatory milestones.”

171 Views

Truveris nets $12.75 mln Series C

Truveris said Friday that it has closed $12.75 million in Series C funding. Canaan Partners led the round with participation from return backers New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round. Based in New York City, Truveris is a platform for pharmacy pricing and benefits analysis.

107 Views

QPID Health nets $12.3 mln Series B funds

QPID Health said Tuesday that it has raised $12.3 million in Series B funding. New Leaf Venture Partners led the round. In conjunction with the funding, Philippe Chambon, managing director at New Leaf Venture Partners, has been added to QPID Health’s board of directors. Headquartered in Boston, QPID Health is a provider of clinical intelligence to healthcare providers.

124 Views

Boston biotech firm Intarcia snags $200 mln

Boston-based biotech company Intarcia Therapeutics has raised $200 million financing. RA Capital led the round with participation from investors that include Farallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners and Quilvest.

126 Views

VC-backed Versartis raises $126 mln for IPO

Versartis has launched its IPO after pricing its 6 million shares at $21 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “VSAR.” Morgan Stanley and Citigroup are the lead underwriters. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency. Its backers include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.

CardioKinetix Completes $48 Million Series E Round

CardioKinetix, a Menlo Park, Calif.-based medical device company, has completed the $23 million second-tranche of its Series E financing, bringing the total round to $48 million. Panorama Capital is the company’s newest investor. It joins previous investors U.S. Venture Partners, JPMorgan Partners, New Leaf Venture Partners, SV Life Sciences, H&Q Healthcare Investors, and H&Q Life Sciences Investors.

Versartis Closes Series C Financing

Versartis, an emerging biotechnology company has completed a $25 million Series C financing lead by new investor Aisling Capital. Also participating in the round were existing investors Index Ventures, New Leaf Venture Partners and Advent Venture PartnersAdvent Life Sciences fund.

Principia Biopharma Inks $12.5M

Principia Biopharma Inc., a biopharmaceutical company focused on immunology, autoimmune diseases, and oncology, has raised $12.5 million. Investors include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.

Awarepoint Picks up $14M

Awarepoint Corp., the real-time location system services provider for healthcare clients, has added $14 million in funding. Heritage Group led the round and was joined by Kleiner Perkins Caufield & Byers, Cardinal Partners, Venrock, Jafco Ventures, Avalon Ventures, New Leaf Venture Partners and Top Tier Capital Partners. PRESS RELEASE: Awarepoint Raises $14 Million in Additional […]

CardioKinetix Appoints Veteran Medical Device Exec

Medical device company CardioKinetix has apointed Maria Sainz as president and chief executive officer. Recently Sainz served as general manager of Stryker Neurovascular, which acquired Concentric Medical in October 2011 under her leadership as president and CEO. CardioKinetix is backed by SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, Panorama Capital, and H&Q […]

PE HUB Community

Join the 12523 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget